Molecularly Targeted Therapy for Lung Cancer : Recent Topics
Journal of Lung Cancer
;
: 1-8, 2008.
Artículo
en Inglés
| WPRIM
| ID: wpr-75530
ABSTRACT
Many clinical trials of molecular target drugs have been done against advanced lung cancer, however, majority did not meet the primary endpoint. Positive studies of EGFR-TKI such as BR21 and Interest used unselected populations of non-small cell lung cancer. It was quite difficult to explain why they were positive. In the present review, the difficulties of clinical trial design in molecular target drugs were discussed based on the differences of the magnitude of antitumor activity and the target tumor cell population between cytotoxic drugs and molecular target therapy
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Pulmón
/
Neoplasias Pulmonares
Idioma:
Inglés
Revista:
Journal of Lung Cancer
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS